摘要
目的 探讨CD44V6在肺鳞癌中的表达及其与肺鳞癌发生发展的相关性。方法 应用免疫组织化学ABC法检测 35例手术切除的新鲜肺鳞癌组织及其癌旁正常肺组织的CD44V6蛋白 ,并将检测结果与患者的临床病理资料进行对照分析。结果 CD44V6在肺鳞癌组织中的阳性表达率为 6 5 .7% ( 2 3/ 35 ) ,而在癌旁正常肺组织中则无表达 ,二者差异有显著性 ( χ2 =34.3 ,P <0 .0 1) ;CD44V6在有淋巴结转移的肺鳞癌组织中的阳性表达率 ( 84.2 % ,16 / 19)明显高于其在无淋巴结转移者中的阳性表达率 ( 4 3 .8% ,7/ 16 ) ( χ2 =6 .3 ,P <0 .0 1) ;CD44V6阳性表达率随肺鳞癌组织分化程度的降低而升高 ,但无统计学意义 ( χ2 =2 .33 ,P >0 .0 5 ) ;CD44V6在Ⅲ +Ⅳ期肺鳞癌中的阳性表达率 ( 86 .7% ,13/ 15 )明显高于其在Ⅰ +Ⅱ期中的阳性表达率 ( 5 0 % ,10 /2 0 ) ( χ2 =5 .1,P <0 .0 1) ;CD44V6阳性表达患者的 3年生存率 ( 30 .4% ,7/ 2 3)明显低于CD44V6阴性者 ( 6 6 .7% ,8/ 12 ) ( χ2 =4.2 ,P <0 .0 5 )。结论 CD44V6可能与肺鳞癌的发生有关 ;CD44V6阳性预示肺鳞癌可能发生淋巴结转移 ,并对肺鳞癌的临床分期起到一定作用 ;
Objective To study the expression of CD44V6 in squamous cell carcinoma of the lung (SCC) and the correlation between the CD44V6 positive expression and the carcinogenesis and development of SCC. Methods Using immunohistochemistry avidin biotin peroxidase complex (ABC) method, CD44V6 protein expression was detected in the fresh cancer tissues and normal tissues adjacent to cancer from 35 patients with SCC. Results CD44V6 presented high expression in cancer tissues (65.7%, 23/35), but it was not detected in the normal tissues adjacent to cancer (χ 2=34.3,P<0.01); compared with SCC without lymph node metastasis (CD44V6 positive rate was 43.8%, 7/16), SCC with lymph node metastasis showed strong expression of CD44V6 (84.2%, 16/19) (χ 2=6.3, P<0.01). CD44V6 expression increased with the cell differentiation of tumor decreasing, but with no statistic significance (χ 2=2.33, P>0.05). There was a distinct difference in CD44V6 expression between stage Ⅰ+Ⅱ (50%, 10/20) and stage Ⅲ+Ⅳ (86.7%, 13/15) (χ 2=5.1, P<0.01) with a tendency of higher stage with higher expression of CD44V6. The 3 year survival rate in patients with CD44V6 positive expression (30.4%, 7/23) was significantly lower than that in patients without CD44V6 expression ( 66.7% , 8/12) (χ 2=4.2, P<0.05). Conclusion The results suggest that CD44V6 may play an important role in the carcinogenesis and the development of SCC and that routine assessment of CD44V6 expression may be valuable for deciding TNM stage of SCC. CD44V6 is considered as an indicator of prognosis for patients with SCC of the lung.
出处
《中国肺癌杂志》
CAS
2001年第5期367-370,共4页
Chinese Journal of Lung Cancer
